

Alison Curnow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7954888/publications.pdf>

Version: 2024-02-01

24
papers

644
citations

623734

14
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

747
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cellular and Molecular Carcinogenic Effects of Radon Exposure: A Review. <i>International Journal of Molecular Sciences</i> , 2013, 14, 14024-14063.	4.1	104
2	Light Dose Fractionation to Enhance Photodynamic Therapy Using 5-Aminolevulinic Acid in the Normal Rat Colon. <i>Photochemistry and Photobiology</i> , 1999, 69, 71-76.	2.5	90
3	The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinic acid photodynamic therapy (MAL-PDT) and subsequent clinical outcome. <i>Lasers in Surgery and Medicine</i> , 2010, 42, 613-619.	2.1	50
4	The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX-induced PDT of Cultured Human Glioma Cells. <i>Photochemistry and Photobiology</i> , 2010, 86, 1154-1160.	2.5	42
5	Direct Comparison of 5-Aminolevulinic Acid and Methyl-Aminolevulinic Acid-Derived Protoporphyrin IX Accumulations Potentiated by Desferrioxamine or the Novel Hydroxypyridinone Iron Chelator CP94 in Cultured Human Cells. <i>Photochemistry and Photobiology</i> , 2007, 83, 766-773.	2.5	41
6	Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. <i>Lasers in Surgery and Medicine</i> , 2006, 38, 325-331.	2.1	32
7	Enhancement of methyl-aminolevulinic acid photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 841-849.	2.5	32
8	An <i>In Vitro</i> Comparison of the Effects of the Iron-Chelating Agents, CP94 and Dexrazoxane, on Protoporphyrin IX Accumulation for Photodynamic Therapy and/or Fluorescence Guided Resection. <i>Photochemistry and Photobiology</i> , 2011, 87, 1419-1426.	2.5	30
9	Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT. <i>Photodiagnosis and Photodynamic Therapy</i> , 2010, 7, 86-97.	2.6	25
10	Biochemical Manipulation via Iron Chelation to Enhance Porphyrin Production from Porphyrin Precursors. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2007, 26, 89-103.	1.2	23
11	Altered cellular redox homeostasis and redox responses under standard oxygen cell culture conditions versus physioxia. <i>Free Radical Biology and Medicine</i> , 2018, 126, 322-333.	2.9	22
12	Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinic acid photodynamic therapy utilizing non-invasive fluorescence imaging and quantification. <i>Photodiagnosis and Photodynamic Therapy</i> , 2011, 8, 30-38.	2.6	21
13	An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy. <i>Lasers in Surgery and Medicine</i> , 2018, 50, 552-565.	2.1	17
14	Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolevulinic acid prodrug. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 25, 157-165.	2.6	17
15	An Evaluation of Root Phytochemicals Derived from <i>Althea officinalis</i> (Marshmallow) and <i>Astragalus membranaceus</i> as Potential Natural Components of UV Protecting Dermatological Formulations. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	4.0	15
16	The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinic acid-based photodynamic cell killing by increasing the generation of reactive oxygen species. <i>Redox Biology</i> , 2016, 9, 90-99.	9.0	14
17	Stress and Unusual Events Exacerbate Symptoms in Meniere's Disease: A Longitudinal Study. <i>Otology and Neurotology</i> , 2018, 39, 73-81.	1.3	14
18	Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy. <i>Cancers</i> , 2019, 11, 72.	3.7	14

#	ARTICLE	IF	CITATIONS
19	The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions. <i>Photodiagnosis and Photodynamic Therapy</i> , 2013, 10, 575-582.	2.6	13
20	Monte Carlo Simulations of Heat Deposition During Photothermal Skin Cancer Therapy Using Nanoparticles. <i>Biomolecules</i> , 2019, 9, 343.	4.0	13
21	The importance of iron chelation and iron availability during PpIX-induced photodynamic therapy. <i>Photonics & Lasers in Medicine</i> , 2015, 4, .	0.2	8
22	Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy. <i>Lasers in Medical Science</i> , 2022, 37, 1155-1166.	2.1	4
23	Light Dose Fractionation to Enhance Photodynamic Therapy Using 5-Aminolevulinic Acid in the Normal Rat Colon. <i>Photochemistry and Photobiology</i> , 1999, 69, 71.	2.5	2
24	Experimental findings utilising a new iron chelating ALA prodrug to enhance protoporphyrin IX-induced photodynamic therapy. , 2019, , .		0